Who Gets Allergic Reactions to Cosentyx?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, carries warnings for hypersensitivity reactions in its prescribing information. These occur in about 1% of patients, typically within days to weeks of starting treatment. Risk factors aren't extensively detailed in clinical data, but reactions are more common in those with a history of drug allergies or atopic conditions like asthma or eczema.[1][2]
What Triggers Reactions During Treatment?
Infusion or injection-site reactions happen in up to 10-15% of users, often mild and resolving without stopping therapy. Severe anaphylaxis is rare (<0.1%), but documented cases link to prior biologic exposure (e.g., TNF inhibitors). No specific genetic or demographic risks stand out beyond general allergy predisposition; age, sex, and dose don't strongly correlate.[1][3]
How Do Past Allergies Affect Risk?
Patients with known allergies to latex (in prefilled syringes) or previous biologics face higher odds. Label contraindicates use in those with severe hypersensitivity to secukinumab or excipients. Cross-reactivity with other IL-17 drugs is unproven but monitored in practice.[1][2]
What Should Patients Watch For?
Early signs include rash, itching, swelling, or breathing issues post-dose. Risk rises with rapid dosing escalation. Clinicians screen for atopy and start with test doses in high-risk cases. Long-term data shows no cumulative allergy risk.[3]
Compared to Other Biologics
Cosentyx's allergy rate matches Dupixent (dupilumab) at ~1-2% but lower than TNF blockers like Humira (up to 5%). Biosimilars, if approved, may carry similar profiles pending data.[1][4]
Sources:
[1] Cosentyx Prescribing Information, Novartis, 2023 - link
[2] FDA Label for Secukinumab - link
[3] Clinical Trials Data, New England Journal of Medicine (SECURE-ASCEND study), 2019 - link
[4] DrugPatentWatch.com (biologic comparisons) - link